1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2016

Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2016" provides an overview of Non-Alcoholic Steatohepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials 28
Prominent Drugs 29
Latest Clinical Trials News on Non-Alcoholic Steatohepatitis 30
Jan 26, 2016: Clinical Trial Results Show Synergy between NuSirt Technology and Metformin in Patients with Type 2 Diabetes 30
Jan 11, 2016: DURECT Announces Initiation of DUR-928 Dosing in Patients 30
Jan 11, 2016: Conatus Initiates Phase 2b ENCORE-NF Clinical Trial of Emricasan in Patients With NASH Fibrosis 30
Jan 06, 2016: DURECT Announces Positive Phase 1 Data for DUR-928 31
Jan 05, 2016: Cempra Doses Initial Patient in Phase 2 Clinical Trial of Solithromycin in NASH 31
Dec 18, 2015: RG-125(AZD4076), a microRNA Therapeutic Targeting microRNA-103/107 Being Developed for the Treatment of NASH in Patients with Type 2 Diabetes/Pre-Diabetes, Enters Phase I Clinical Development 32
Dec 10, 2015: NuSirt Biopharma Receives FDA Fast Track Designation for Non-Alcoholic Fatty Liver Disease Treatment 32
Dec 08, 2015: Tobira Therapeutics Announces Data Presentations Highlighting Cenicriviroc at HEP DART 2015 33
Dec 07, 2015: Intercept Pharmaceuticals Announces Initiation of Prospective Trial to Explore Effect of Combined OCA and Statin Therapy on Lipid Metabolism in NASH Patients 34
Nov 23, 2015: Can-Fite Announces Compelling Pre-Clinical Data on CF102 in the Treatment of Non-Alcoholic Steatohepatitis 35
Nov 19, 2015: MediciNova to Initiate Clinical Trial Evaluating MN-001 in NASH Patients With Hypertriglyceridemia 36
Nov 18, 2015: NASH Clinical Trail Surpasses 25% Patient Recruitment Milestone 36
Nov 16, 2015: GENFIT Announces Pivotal Phase 3 Clinical Trial of Elafibranor in NASH Following Regulatory Input 37
Nov 14, 2015: Intercept Presents New Data Analyses on Non-Invasive Liver Testing From FLINT Trial of Obeticholic Acid in Nonalcoholic Steatohepatitis at AASLD 2015 38
Nov 12, 2015: Albireo to Present A4250 Clinical Data at the 2015 AASLD Annual Meeting 39
Nov 11, 2015: DeuteRx Presents DRX-065 for the Treatment of NASH at the Annual Meeting of the American Association for the Study of Liver Diseases 39
Nov 09, 2015: NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD's The Liver Meeting 2015 39
Clinical Trial Profile Snapshots 41
Appendix 202
Abbreviations 202
Definitions 202
Research Methodology 203
Secondary Research 203
About GlobalData 204
Contact Us 204
Disclaimer 204
Source 205

List of Tables
Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Region, 2016* 7
Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10
Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13
Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 14
Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 15
Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, E7 Countries (%), 2016* 18
Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Phase, 2016* 21
Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22
Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Non-Alcoholic Steatohepatitis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26
Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List of Figures
Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Region (%), 2016* 7
Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 13
Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14
Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 15
Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, E7 Countries (%), 2016* 18
Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21
Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22
Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Non-Alcoholic Steatohepatitis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26
Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 203

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glutamyl Aminopeptidase ...

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H2 2016

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Leukotriene A 4 Hydrolase (LTA 4 Hydrolase ...

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H2 2016

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.